AGILON HEALTH INC (AGL)
US00857U1079 - Common Stock
We assign a fundamental rating of 3 out of 10 to AGL. AGL was compared to 114 industry peers in the Health Care Providers & Services industry. AGL has a bad profitability rating. Also its financial health evaluation is rather negative. AGL is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
AGL had negative earnings in the past year.
AGL had a negative operating cash flow in the past year.
In the past 5 years AGL always reported negative net income.
In the past 5 years AGL always reported negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -18.40%, AGL is not doing good in the industry: 76.32% of the companies in the same industry are doing better.
AGL has a Return On Equity of -66.94%. This is in the lower half of the industry: AGL underperforms 73.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -18.4% | ||
| ROE | -66.94% | ||
| ROIC | N/A |
ROA(3y)-15.66%
ROA(5y)-26.12%
ROE(3y)-29.05%
ROE(5y)-181.24%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 2.00%, AGL is doing worse than 84.21% of the companies in the same industry.
AGL's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for AGL so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 2% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-23.83%
GM growth 5YN/A
2. Health
2.1 Basic Checks
AGL does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AGL has been reduced compared to 1 year ago.
Compared to 1 year ago, AGL has an improved debt to assets ratio.
2.2 Solvency
AGL has an Altman-Z score of 1.56. This is a bad value and indicates that AGL is not financially healthy and even has some risk of bankruptcy.
AGL has a Altman-Z score (1.56) which is comparable to the rest of the industry.
AGL has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.
With a decent Debt to Equity ratio value of 0.06, AGL is doing good in the industry, outperforming 76.32% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.56 |
ROIC/WACCN/A
WACC9.04%
2.3 Liquidity
AGL has a Current Ratio of 1.29. This is a normal value and indicates that AGL is financially healthy and should not expect problems in meeting its short term obligations.
AGL has a Current ratio of 1.29. This is comparable to the rest of the industry: AGL outperforms 42.11% of its industry peers.
A Quick Ratio of 1.29 indicates that AGL should not have too much problems paying its short term obligations.
AGL has a Quick ratio (1.29) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.29 | ||
| Quick Ratio | 1.29 |
3. Growth
3.1 Past
The earnings per share for AGL have decreased strongly by -254.55% in the last year.
The Revenue has grown by 27.75% in the past year. This is a very strong growth!
The Revenue has been growing by 52.45% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-254.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-262.5%
Revenue 1Y (TTM)27.75%
Revenue growth 3Y52.45%
Revenue growth 5YN/A
Sales Q2Q%19.35%
3.2 Future
AGL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 48.20% yearly.
Based on estimates for the next years, AGL will show a very strong growth in Revenue. The Revenue will grow by 21.92% on average per year.
EPS Next Y20.08%
EPS Next 2Y22.76%
EPS Next 3Y25.08%
EPS Next 5Y48.2%
Revenue Next Year34.3%
Revenue Next 2Y28.14%
Revenue Next 3Y25.94%
Revenue Next 5Y21.92%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
AGL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AGL. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
AGL's earnings are expected to grow with 25.08% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.76%
EPS Next 3Y25.08%
5. Dividend
5.1 Amount
AGL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AGILON HEALTH INC
NYSE:AGL (11/11/2024, 8:19:32 PM)
After market: 2.12 -0.04 (-1.85%)2.16
+0.32 (+17.39%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap889.96M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -18.4% | ||
| ROE | -66.94% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 2% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover2.56
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.29 | ||
| Quick Ratio | 1.29 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-254.55%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y20.08%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)27.75%
Revenue growth 3Y52.45%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y